71RO Sustained remission and long-term survival outcomes with dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

V.S. Sukhin; T.J. Herzog; L. Gilbert; A. Koliadi; C. Mathews; S.E. Gill; G. Ronzino; I. Podzielinski; S. Kommoss; M. Edelson; A.M. Thijs; R W Holloway; B.J. Monk; E.M. Miller; T. Myers; J. Diaz; B. Patel; L. Austin; T. Jakobi Nøttrup; M.A. Powell

doi:10.1016/j.esmoop.2026.108097

July 1, 2026ESMO OpenOpen Access

71RO Sustained remission and long-term survival outcomes with dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the long-term efficacy and safety of dostarlimab plus chemotherapy in patients with dMMR/MSI-H endometrial cancer.
Study design (ENGOT-EN6-NSGO/GOG-3031/RUBY) with NCT03981796 registry ID.
Involved patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Follow-up duration of 4 years to assess long-term outcomes.
Dostarlimab plus chemotherapy significantly improved progression-free survival (PFS) compared to previous treatments.
Clinically meaningful overall survival (OS) benefits were observed in the treatment group.
Patients showed characteristics of long-term disease control beyond the initial treatment phase.

Implication

Shows improved progression-free survival and overall survival in endometrial cancer, suggesting effectiveness of the treatment combination.

Abstract

Dostarlimab + carboplatin-paclitaxel (DOST+CP) demonstrated statistically significant PFS and clinically meaningful OS benefits in patients (pts) with dMMR/MSI-H primary advanced or recurrent endometrial cancer (pA/R EC) in Part 1 of the phase III RUBY trial (NCT03981796). Here, we report updated efficacy with 4 y of follow-up in pts with dMMR/MSI-H pA/R EC and further summarized characteristics of pts with long-term disease control.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sukhin et al. (2026) studied this question.

synapsesocial.com/papers/6a48a42489561a0c2d78dacf https://doi.org/10.1016/j.esmoop.2026.108097

View Full Paper

Ask AI

Bookmark

Share

71RO Sustained remission and long-term survival outcomes with dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Key Points

Implication

Abstract

Discussion

Cite This Study

71RO Sustained remission and long-term survival outcomes with dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from ESMO Open

Keep reading

More related papers

More from ESMO Open